FasL蛋白在人类非小细胞肺癌中的表达及其临床意义

目的　探讨Fas配体 (FasL)在人类非小细胞肺癌 (NSCLC)中的表达及临床意义。方法　应用免疫组织化学方法检测FasL蛋白在 32例手术切除的NSCLC中的表达情况。结果　FasL在本组 32例NSCLC中的阳性表达百分数为 3.0 %～ 98.7% ,平均(6 2 .0± 32 .0 ) % ,其中在肺腺癌中的平均阳性表达百分数为 (80 .5± 2 1 .2 ) % ,在肺鳞癌中为 (5 2 .3± 32 .8) % ,FasL蛋白在两种不同病理类型的肺癌中阳性表达水平差异显著 (P <0 .0 5 )。但在不同分化程度和不同外科病理分期 (PathologicalTNMstage ,pTNM)的NSCLC中FasL蛋白表达差异不显著 (P >0 .0 5 )。结论　FasL在NSCLC中的表达提示NSCLC具有反杀伤免疫细胞的能力 ,并可能是肺腺癌较易发生早期转移的重要原因

Expression of Fas ligand protein in human non-small cell lung cancer and its clinical significance

Objective　To explore the expression of Fas ligan d (FasL) protein in human non-small cell lung cancer (NSCLC) and its clinic al significance. Methods　Expression of FasL protein was detecte d by immunohistochemical method in 32 resected tumors of NSCLC. Results 　FasL protein was detected in all of these 32 resected tumors with variant pos itive expression levels ranging from 3.0% to 98.7% ［mean (62.0±32.0)%］. T here wa s significant difference between the tumors of different pathological types no s ignificant difference was found between the tumors of different differentiation nor among the tumors of different pTNM stages (P>0.05). Conclusion　 The results indicated that NSCLC can counterattack the immune cells of t he body and may be the molecular basis for the easily metastasis of adenocarcino ma to in the early stage.